Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996825 · ClinicalTrials.gov registry record · Phase 1
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02996825 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 44 participants.
The verdict
NCT02996825, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer that has come back. Mirvetuximab soravtansine is a monoclonal antibody, called mirvetuximab, linked to a chemotherapy drug called DM4. Mirvetuximab attaches to FOLR1 positive cancer cells in a targeted way and delivers DM4 to kill them. Drugs used in the chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mirvetuximab soravtansine and gemcitabine may work better in treating patients with FRalpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Gemcitabine
- DRUG Gemcitabine Hydrochloride
- OTHER Pharmacological Study
- BIOLOGICAL Mirvetuximab Soravtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2024-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02996825
The ClinicalTrials.gov registry entry for NCT02996825 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02996825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02996825 about?
NCT02996825 is a clinical study titled "Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer". This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer that has come back. Mirvetuxim...
What is the current status of trial NCT02996825?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2017-03-22. Estimated completion is 2024-02-09.
What interventions are being tested in trial NCT02996825?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Gemcitabine (DRUG), Gemcitabine Hydrochloride (DRUG), Pharmacological Study (OTHER), Mirvetuximab Soravtansine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02996825?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.